165 related articles for article (PubMed ID: 35691075)
1. Saikosaponin D attenuates metabolic associated fatty liver disease by coordinately tuning PPARα and INSIG/SREBP1c pathway.
Gu Y; Duan S; Ding M; Zheng Q; Fan G; Li X; Li Y; Liu C; Sun R; Liu R
Phytomedicine; 2022 Aug; 103():154219. PubMed ID: 35691075
[TBL] [Abstract][Full Text] [Related]
2. Danthron ameliorates obesity and MAFLD through activating the interplay between PPARα/RXRα heterodimer and adiponectin receptor 2.
Ma C; Wang Z; Xia R; Wei L; Zhang C; Zhang J; Zhao L; Wu H; Kang L; Yang S
Biomed Pharmacother; 2021 May; 137():111344. PubMed ID: 33581653
[TBL] [Abstract][Full Text] [Related]
3. Saikosaponin A and D Inhibit Adipogenesis via the AMPK and MAPK Signaling Pathways in 3T3-L1 Adipocytes.
Lim SH; Lee HS; Han HK; Choi CI
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768840
[TBL] [Abstract][Full Text] [Related]
4. Molecular Mechanisms of Fucoxanthin in Alleviating Lipid Deposition in Metabolic Associated Fatty Liver Disease.
Yang S; Li J; Yan L; Wu Y; Zhang L; Li B; Tong H; Lin X
J Agric Food Chem; 2024 May; 72(18):10391-10405. PubMed ID: 38669300
[TBL] [Abstract][Full Text] [Related]
5. Si-Ni-San Reduces Hepatic Lipid Deposition in Rats with Metabolic Associated Fatty Liver Disease by AMPK/SIRT1 Pathway.
Zhang N; Liu T; Wang J; Xiao Y; Zhang Y; Dai J; Ma Z; Ma D
Drug Des Devel Ther; 2023; 17():3047-3060. PubMed ID: 37808345
[TBL] [Abstract][Full Text] [Related]
6. α-Lactalbumin Peptide Asp-Gln-Trp Ameliorates Hepatic Steatosis and Oxidative Stress in Free Fatty Acids-Treated HepG2 Cells and High-Fat Diet-Induced NAFLD Mice by Activating the PPARα Pathway.
Chen H; Ma Y; Qi X; Tian J; Ma Y; Niu T
Mol Nutr Food Res; 2023 Aug; 67(16):e2200499. PubMed ID: 37354055
[TBL] [Abstract][Full Text] [Related]
7. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
Huang K; Du M; Tan X; Yang L; Li X; Jiang Y; Wang C; Zhang F; Zhu F; Cheng M; Yang Q; Yu L; Wang L; Huang D; Huang K
J Hepatol; 2017 May; 66(5):962-977. PubMed ID: 27979751
[TBL] [Abstract][Full Text] [Related]
8. Niga-ichigoside F1 ameliorates high-fat diet-induced hepatic steatosis in male mice by Nrf2 activation.
Xia SF; Shao J; Zhao SY; Qiu YY; Teng LP; Huang W; Wang SS; Cheng XR; Jiang YY
Food Funct; 2018 Feb; 9(2):906-916. PubMed ID: 29309075
[TBL] [Abstract][Full Text] [Related]
9. Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity.
Yan F; Wang Q; Lu M; Chen W; Song Y; Jing F; Guan Y; Wang L; Lin Y; Bo T; Zhang J; Wang T; Xin W; Yu C; Guan Q; Zhou X; Gao L; Xu C; Zhao J
J Hepatol; 2014 Dec; 61(6):1358-64. PubMed ID: 25016220
[TBL] [Abstract][Full Text] [Related]
10. Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
Araújo S; Soares E Silva A; Gomes F; Ribeiro E; Oliveira W; Oliveira A; Lima I; Lima MDC; Pitta I; Peixoto C
Eur J Pharmacol; 2016 Oct; 788():306-314. PubMed ID: 27349145
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic role of Artemether in the prevention of hepatic steatosis through miR-34a-5p/PPARα pathway.
Chen L; Yu S; Hong S; Lin X; Zhu X; Cao X; Li Y; Xiao H
Drug Dev Res; 2023 Apr; 84(2):156-171. PubMed ID: 36541217
[TBL] [Abstract][Full Text] [Related]
12. Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis.
Li J; Xie S; Teng W
Nutrients; 2021 Dec; 14(1):. PubMed ID: 35010950
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.
Huang Y; Lang H; Chen K; Zhang Y; Gao Y; Ran L; Yi L; Mi M; Zhang Q
Appl Physiol Nutr Metab; 2020 Mar; 45(3):227-239. PubMed ID: 31173696
[TBL] [Abstract][Full Text] [Related]
14. The HIF-2α/PPARα pathway is essential for liraglutide-alleviated, lipid-induced hepatic steatosis.
Wang H; Wang L; Li Y; Luo S; Ye J; Lu Z; Li X; Lu H
Biomed Pharmacother; 2021 Aug; 140():111778. PubMed ID: 34062416
[TBL] [Abstract][Full Text] [Related]
15. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
[TBL] [Abstract][Full Text] [Related]
16. PPARα is one of the key targets for dendrobine to improve hepatic steatosis in NAFLD.
Xu Y; Wang M; Luo Y; Liu H; Ling H; He Y; Lu Y
J Ethnopharmacol; 2024 Apr; 323():117684. PubMed ID: 38171466
[TBL] [Abstract][Full Text] [Related]
17. Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models.
Zhang Y; Meng T; Zuo L; Bei Y; Zhang Q; Su Z; Huang Y; Pang J; Xiang Q; Yang H
Mar Drugs; 2017 Jun; 15(6):. PubMed ID: 28587208
[TBL] [Abstract][Full Text] [Related]
18. Loss of NAT10 alleviates maternal high-fat diet-induced hepatic steatosis in male offspring of mice.
Zhang QR; Zhang JB; Shen F; Xue R; Yang RX; Ren TY; Fan JG
Obesity (Silver Spring); 2024 Jul; 32(7):1349-1361. PubMed ID: 38816990
[TBL] [Abstract][Full Text] [Related]
19. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
[TBL] [Abstract][Full Text] [Related]
20. Honokiol activates the LKB1-AMPK signaling pathway and attenuates the lipid accumulation in hepatocytes.
Seo MS; Kim JH; Kim HJ; Chang KC; Park SW
Toxicol Appl Pharmacol; 2015 Apr; 284(2):113-24. PubMed ID: 25737164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
